Skip to content
Search

Latest Stories

3 dead, 5 seriously ill due to listeria after eating chocolate dessert

The outbreak has raised serious concerns due to its impact on vulnerable hospital patients

 Listeria

Health officials have launched an investigation to determine the full extent of the contamination

Getty Images

Three people have died and five others have fallen seriously ill following a listeria outbreak linked to a chocolate dessert supplied to NHS hospitals across the UK. Health officials have launched an investigation to determine the full extent of the contamination, which has prompted a nationwide recall of chilled desserts from hospitals and care homes.

The Food Standards Agency (FSA) has identified mousses and ice creams made by Cool Delight Desserts as the suspected source of the listeria outbreak. This recall covers all chilled desserts including mousses, ice creams, ice cream rolls, and yoghurts supplied by the company to NHS facilities. The action is being taken as a precaution while health authorities continue their investigation.


The five patients affected by the outbreak, identified between May and December 2024, were aged between 68 and 89. The cases have been reported across the UK, including in Yorkshire, the Humber, the North West, the West Midlands, and Wales. The outbreak has raised serious concerns due to its impact on vulnerable hospital patients, especially those with underlying immunocompromising conditions.

Cool Delight Desserts as the suspected source of the listeria outbreakCool Delights

Only one of the three deaths has been directly attributed to Listeria monocytogenes, according to health officials. Nevertheless, all five individuals who contracted the illness required hospitalisation due to their weakened immune systems. The FSA confirmed that these patients were already dealing with serious health issues, which made them more susceptible to severe listeria infections.

Listeriosis is a serious bacterial infection caused by Listeria monocytogenes, a pathogen commonly found in contaminated food. While it is rare in healthy individuals, it can be life-threatening for vulnerable groups such as the elderly, pregnant women, babies, and people with compromised immune systems. Listeriosis symptoms are similar to the flu, including high fever, muscle aches, chills, nausea, and vomiting. In severe cases, the infection can cause life-threatening complications, such as meningitis.

Although the levels of listeria detected in the contaminated desserts were below the regulatory threshold of 100 colony-forming units per gram, the FSA noted that immunocompromised patients are more likely to suffer serious consequences from the infection. The bacterium was detected in two different mousse flavours, chocolate and vanilla and strawberry and vanilla, during routine testing at an NHS hospital in the South West of England.

Tina Potter, head of incidents at the FSA, confirmed that they are working closely with other health bodies to identify the exact cause of the outbreak. The FSA is coordinating with the UK Health Security Agency (UKHSA), the NHS, the Department of Health and Social Care, and local authorities to remove the potentially contaminated desserts from the supply chain. Potter emphasised that the food business responsible for the desserts, Cool Delight Desserts, is fully cooperating with the investigation and has initiated a product withdrawal as a precaution.

Dr Gauri Godbole, deputy director for gastrointestinal infections at the UKHSA, reiterated that the cause of the outbreak has not yet been conclusively identified. However, laboratory testing has suggested a link to a specific type of dessert served in NHS hospitals. The desserts in question are not available to the general public through retailers but are distributed in healthcare settings.

As a precaution, NHS Trusts and care providers have been instructed to stop serving these desserts until the investigation is complete. Hospital staff have been asked to check refrigerators and remove any remaining products that could pose a risk to patients.

The FSA has also warned the public that listeria-contaminated food may not show obvious signs of spoilage, but can still cause dangerous infections. Listeria is commonly found in unpasteurised milk, soft cheeses, pre-packed sandwiches, and other ready-to-eat foods. It can also be present in raw food, soil, and the droppings of various animals, including mammals, birds, and fish.

While the FSA investigates this outbreak, it is worth noting that listeriosis cases have been a concern for health authorities for years. In 2023, there were 177 reported cases of listeriosis in England and Wales, with 32 deaths. Of these deaths, 11 were directly linked to listeriosis. Previous outbreaks have been associated with foods such as smoked fish, semi-soft cheese, and beef products.

This latest outbreak has once again highlighted the need for strict food safety standards, especially in settings where vulnerable patients are being cared for. The public is urged to remain vigilant and avoid high-risk foods, while health authorities continue to investigate and ensure the safety of the NHS food supply.

More For You

heatwave

The Met Office and UK Health Security Agency (UKHSA) have issued amber heat-health alerts

Getty Images

Doctors warn of hidden signs of heat stroke as UK issues amber alerts

Key points

  • Amber heat-health alerts issued as temperatures approach 35°C in parts of the UK.
  • Early signs of heat stroke include confusion, slurred speech, and dizziness.
  • Heat exhaustion can develop into heat stroke if not treated within 30 minutes.
  • At-risk groups include the elderly, young children, and those with health conditions.
  • NHS and health experts urge people to stay hydrated, cool, and avoid midday sun.

Medical experts are urging the public to remain alert for the early signs of heat stroke, as temperatures across parts of England are expected to reach up to 35°C. The Met Office and UK Health Security Agency (UKHSA) have issued amber heat-health alerts, warning that extreme heat can have serious health impacts. Doctors stress that symptoms can begin subtly, making early intervention crucial.

Heat alerts across multiple regions

Amber-level warnings are in effect for the West Midlands, East Midlands, Yorkshire and the Humber, South East, South West, London, and the East of England.

Keep ReadingShow less
weight loss injections UK

The importance of vigilance as demand for these weight loss and diabetes drugs continues to grow

iStock

Hundreds report pancreas issues linked to weight loss injections as UK launches safety study

Key points

  • Almost 400 reports of acute pancreatitis linked to weight loss and diabetes jabs have been filed in the UK
  • Most cases involve popular GLP-1 drugs including Ozempic, Wegovy, and Mounjaro
  • Health officials are investigating possible genetic causes behind the side-effects
  • Patients hospitalised with pancreatitis encouraged to report symptoms via MHRA’s Yellow Card scheme
  • Adverse drug reactions cost the NHS an estimated £2.2bn annually

Health watchdog investigates spike in serious side-effects from GLP-1 drugs

UK health authorities have launched a study into the side effects of popular weight loss and diabetes drugs following a spike in reported cases of acute pancreatitis. Nearly 400 reports have been received via the Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, which monitors side effects and adverse reactions related to medicines and medical devices.

The medicines involved are GLP-1 receptor agonists – including semaglutide (marketed as Ozempic and Wegovy), liraglutide, and tirzepatide (branded as Mounjaro). The Yellow Card data shows that 181 of the cases involved tirzepatide alone.

Keep ReadingShow less
Weight Loss Drug

Health officials expect the rollout to benefit around 220,000 adults over the next 3 years

iStock

NHS GPs to prescribe Mounjaro in nationwide obesity treatment plan

Key points

  • NHS GPs in England can now prescribe Mounjaro (tirzepatide) for weight loss
  • The programme aims to support 220,000 people over three years
  • Eligible patients must have a BMI over 40 and at least four obesity-related health issues
  • GP leaders raise concerns over increased workload
  • Pharmacists urge a broader weight management approach

NHS expands obesity treatment with Mounjaro

The NHS in England is set to begin prescribing Mounjaro, a weight loss injection, through GP surgeries starting Monday. The move marks the first time family doctors will be authorised to directly prescribe the anti-obesity drug tirzepatide as part of a wider national health initiative.

Health officials expect the rollout to benefit around 220,000 adults over the next three years. The drug will be made available to those with a body mass index (BMI) above 40 who also suffer from at least four other obesity-related conditions, such as type 2 diabetes, high blood pressure, or sleep apnoea.

Keep ReadingShow less
UK heatwave deaths

Around 85% of the projected deaths are likely to involve people over the age of 65

iStock

Scientists warn current UK heatwave may cause nearly 600 early deaths

Almost 600 premature deaths are expected to occur during the ongoing heatwave affecting England and Wales, according to a new rapid analysis by leading scientists. The majority of fatalities are projected among older adults, with London and the West Midlands likely to be the worst-affected areas.

Climate change driving deadly temperatures

Researchers say the extreme temperatures, which have reached 32°C in parts of south-east England, would have been nearly impossible without the influence of human-caused climate change. Pollution from burning fossil fuels has raised the likelihood of such heatwaves by around 100 times, experts say.

Keep ReadingShow less
Amycretin

'The Lancet' and presentations at the American Diabetes Association’s 2025

iStock

New weight-loss pill Amycretin shows greater impact than jabs, study finds

A new weight-loss drug, amycretin, has delivered the most significant results yet for appetite-suppressing GLP-1 medications, according to two newly published studies in The Lancet and presentations at the American Diabetes Association’s 2025 Scientific Sessions in Chicago.

Record weight loss from Amycretin injections

Researchers found that participants receiving high-dose weekly injections of amycretin lost 24.3 per cent of their body weight over 36 weeks. This outcome surpasses the results seen in longer trials involving other GLP-1 drugs such as tirzepatide (sold as Mounjaro), which previously led the field with an average weight loss of 20 per cent over 72 weeks.

Keep ReadingShow less